Germany’s PharmaSGP Predicts Market Turnaround Despite Difficult First Half
Executive Summary
Germany's PharmaSGP blamed ongoing lockdowns for falling first-half sales, but said it could see light at the end of the tunnel, with the OTC market expected to recover in the second half of the year.
You may also be interested in...
PharmaSGP Capitalizes On End Of Pandemic Restrictions
Germany's PharmaSGP took full advantage of the return of consumers to pharmacies across Europe as pandemic restrictions were lifted to post a 66% jump in consumer health sales during the first half of 2022.
EU Business News: Ceres Acquires GlobiFer Iron Supplement, PharmaSGP Achieves Record Quarter
The latest European consumer healthcare business news: Belgium's Ceres Pharma expands its portfolio with GlobiFer; and PharmaSGP achieves its best ever quarter thanks to the recovery of the OTC market.
GSK Offloads Popular German OTCs To PharmaSGP
GSK divests non-core German OTC portfolio to local player PharmaSGP, which says it has gained "established brands" in the pain-relief and sleep-aid categories.